Qure.ai develops AI software for medical imaging and care coordination. The company's qXR product is positioned as a chest X-ray reporting tool that can identify findings across multiple anatomical regions and generate pre-filled reports. Vendor materials describe deployment in teleradiology, emergency, and screening settings, while technical documentation specifies input requirements and output formats. This profile examines documented product functions, workflow details, organizational contexts, and implementation boundaries. [1][4][6][7]

Documented qXR Functions and Outputs

The qXR product page describes AI for chest X-ray reporting with findings across lungs, pleura, mediastinum, bones, diaphragm, and heart. Vendor materials state that qXR can provide pre-read assistance, pre-filled reports, and AI overlays. The product page also lists use cases including segregation of unremarkable chest X-rays, high-volume reporting for teleradiology and immigration screenings, active case finding for tuberculosis and lung cancer screening, and identification of incidental findings for lung cancer and heart failure. [1]

Technical documentation specifies the output files qXR can generate. These include findings and segmentation presented as GSPS overlay in DICOM format, a PDF report with findings summary, a PDF report encapsulated as DOC modality in DICOM format, findings in structured report format as DICOM, and findings with segmentation presented as secondary capture in DICOM format. The documentation also indicates that generated outputs are available as a response payload for the result call, with output files accessible as URLs. [4][5]

Input Requirements and Processing Workflow

The qXR API documentation lists acceptance criteria for chest X-ray processing. Accepted views are PA or AP, with a minimum resolution of 1440 by 1440. Processing occurs at the instance level. Patient age must be greater than six years, with patients under six years excluded. Accepted patient positions are erect or supine. Supported modalities are CR, DR, DX, and RF. Files must be in valid DICOM format, and the body part examined must be chest. [6]

The Qure.ai App user manual describes a workflow in which the app receives DICOM studies via DICOM network protocol from PACS or modality systems, or DICOM can be imported from a local system. The received study is processed on Qure's cloud server, and AI-processed reports are displayed on the app. The manual states that reports can be read, viewed, manipulated, and shared with other radiologists, consultants, and doctors. [7]

Reimbursement Considerations for AI-Enabled Pathways

Qure.ai's US site states that products within the lung cancer and neuro pathways are billable under CMS-issued CPT codes such as 0721T and 0727T. The site states that Qure works with revenue-cycle teams to align documentation, coding, and payer engagement within existing imaging and follow-up workflows. The site advises consulting local medical-necessity and documentation policies before billing and prior authorization. [2]

Regulatory Clearances and Certifications

Qure.ai's regulatory page states that the company holds MDSAP certification for ISO 13485:2016 from TUV SUD, covering regulatory standards from the US FDA, Australian TGA, Brazilian ANVISA, Health Canada, and Japan's Ministry of Health. The page also states that Qure.ai is ISO/IEC 27001 certified for information security management. [3]

For the European Economic Area, the regulatory page states that qXRv3.1 and qERv2.0 received Class IIa CE certification under the EU Medical Device Directive, while qXRv4.0, qER-NCCT, qCT, and qMSK received Class IIb CE certification under the EU Medical Device Regulation. The page also mentions approvals in Latin America, Saudi Arabia, Indian CDSCO class B, and ASEAN member countries, with specific product approval details available upon request. [3]

A February 2026 news release states that the FDA granted 510(k) Class II clearance for qXR-Detect, a computer-assisted detection radiography solution. The release states that this clearance brings Qure.ai's total FDA cleared indications to 26 across 9 products for X-ray and CT, and that the company has more than 65 CE certified indications. The release also states that qXR-Detect is the only chest X-ray CADe device cleared by the FDA with a Predetermined Change Control Plan. [8]

Organizational Settings and Deployment Options

Vendor materials describe qXR deployment across multiple organizational contexts. The product page states that qXR has been used in more than 90 countries and 3,100 or more sites, with 10.7 million scans processed and training on 9 million scans. The page also states that qXR can be deployed on cloud or on-premise and is available in multiple languages on mobile and web. [1]

The Qure.ai App user manual describes the app as an on-cloud image viewing software supporting multi-modality imaging, including CT and X-ray, on mobile and desktop devices. The manual states that the app reduces turnaround time by utilizing Qure's AI-powered imaging solutions such as qXR and qER, and that it enables early intervention and streamlines existing patient-care workflows. [7]

Related Products and Platform Scope

Qure.ai's US site describes a broader platform that includes qCT LN Quant for automated nodule quantification on CT scans, with volumetric segmentation and risk stratification based on Lung-RADS and Brock score, as well as follow-up recommendations based on Fleischner guidelines. The site also describes qTrack as a follow-up management platform supporting radiology workflow orchestration and longitudinal tracking across imaging and follow-up. [2]

The user manual describes qER as a product that screens head CT scans for intracranial hemorrhage, cranial fractures, midline shift, mass effect, infarcts, and atrophy. The manual states that qER alerts neuro-critical care teams about 11 non-contrast head CT findings, enabling faster decision-making for timely care. The manual also states that the software provides a priority flag for critical scans, an overlay highlighting the location and measurements of abnormal findings, and PDF, text, or structured reports quantifying the volume and extent of abnormalities. [7]